

June 2, 2017



# OncoSec to Present at LD Micro Invitational

SAN DIEGO, June 2, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will be featured as a presenting company at the upcoming LD Micro Invitational to be held on June 6-7, 2017 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Punit Dhillon, CEO and President of OncoSec, will provide a corporate overview on Wednesday, June 7, 2017 at 2:00 PM PT/ 5:00 PM ET and will be available to meet with investors. If you would like to attend the Company's presentation or schedule a meeting, please click on the following link: <https://www.ldmicro.com/events>.

To view the live webcast, please access the following link at the time of the presentation: <http://www.wsw.com/webcast/ldmicro12/oncs>. An archived version of the webcast will be available for 90 days on OncoSec's website: <http://www.oncosec.com>.

## About OncoSec Medical Incorporated

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit [www.oncosec.com](http://www.oncosec.com).

## CONTACT:

Investor Relations  
OncoSec Medical Incorporated  
855-662-6732  
[investors@oncosec.com](mailto:investors@oncosec.com)

Media Relations  
OncoSec Medical Incorporated  
855-662-6732  
[media@oncosec.com](mailto:media@oncosec.com)



ONCOSEC<sup>TM</sup>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/oncosec-to-present-at-ld-micro-invitational-300467674.html>

SOURCE OncoSec Medical Incorporated